Antibody Therapeutics Xchange East Coast 2019
- When is the right time to use bispecific technology?
- Can predictions be made on targets which are most amenable to bispecific technology?
- Cases in which a single agent combination would be optimal?
- Would certain targets benefit from more innovative biologic combinations?
Senior Director, Head of Protein Engineering & Expression
Angela began her career working on lysosomal storage disorders at Transkaryotic Therapies which was purchased by Shire in 2005. At Shire, Angela held leadership positions spanning all technical fields involved in designing and testing protein therapeutic development candidates. In 2014 Angela became Head of Protein and Antibody Engineering at Shire, where her team is responsible for delivering comprehensive data packages for optimized protein and antibody therapeutics for a diverse pipeline of rare diseases. Takeda purchased Shire in January 2019. Angela received her bachelors degree from St. Olaf College, and a PhD in Biochemistry and Molecular Biology from the University of New Hampshire.
- Optimal discovery method versus available budget – how do we decide the best path?
- Animal immunizations, natural human antibody repertoire library selection, or synthetic library selection – what are the pros and cons?
- What is the best strategy for choosing the lead candidate selection criteria and at what point should a functional study be integrated – early or later?
- What are the ideal immunization and selection tools? If appropriate cell lines and/or recombinant proteins are not available?
Head of Contract Research
Debby Kruijsen obtained a PhD in immunology at the University of Utrecht, The Netherlands in 2011, studying the role of antibodies in affecting antigen presentation and subsequent Respiratory Syncytial Virus specific T cell activation. In 2012, Debby joined ModiQuest Research, an ImmunoPrecise Antibodies, Ltd. company, as a scientist supervising hybridoma antibody discovery projects. She was promoted in 2013 to Head of Contract Research for ModiQuest Research were she is responsible for the daily management within the CRO and is a member of the business development group.
- How does disease indication impact target selection?
- What weight do you give to various target identification strategies (e.g. functional screening, gene or protein expression data, pathway analysis, clinical data, etc) for prioritizing targets?
- When is it okay to be a follow-on compound?
Vice President R&D
Matthew Robinson is VP, Research & Development for Immunome. Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Prior to joining Immunome he was on the faculty at Fox Chase Cancer Center and led a research laboratory developing antibody-based molecules for the detection and treatment of cancer. Matthew co-founded RAbD Biotech, a company focused on the computational design of antibodies and served on the Scientific Advisory Boards of a number of antibody-focused biotechnology companies. He earned a Ph.D. from University of Rochester and performed post-doctoral work at Yale University.
- How has our increased understanding of disease biology, mechanism of action, and molecular players increased our ability to develop biotherapeutics involving targets that were previously thought as undruggable?
- What has changed in the antibody technology landscape that has forced drug discovery scientists to think differently about when to use a biologic against a given target?
- Are targets in the brain the final frontier, and how will we get there?
- Multi-specific conditional targeting half-life extended drug-conjugated biologics? Are we trying to be too clever in our engineering efforts to access difficult drug targets?
Senior Director, Discovery Biologics
Blaine Stine has over 18 years of research and leadership experience in the biopharmaceutical industry with broad experience in protein biochemistry, protein analytics, CMC, and biologics discovery. He currently leads a team of 40 scientists in Worcester MA responsible for antibody discovery, engineering, production and screening supporting all AbbVie therapeutic areas. Prior to his current role as Senior Director in Global Biologics R&D, Blaine has held strategic positions at AbbVie including Principle Research Scientist Protein Analytics, and Associate Director Biologics CMC.
Blaine attended the University of California San Diego (B.A. Molecular Biology) and Northwestern University (Ph.D. in Biochemistry).